Clinical trials: Disability
Developmental Language Disorder and Language Impairment, Specific Language Impairment
Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading II
Children with developmental language disorder (DLD; also referred to as specific language impairment) experience a significant deficit in language ability that is longstanding and harmful to the children's academic, social, and…
- Conditions
- Developmental Language Disorder and Language Impairment, Specific Language Impairment, Language Development
- Trial name
- NCT07048392
- Testing
- Retrieval-based word learning: Repeated Spaced Retrieval condition, Retrieval-based word learning: Repeated Study condition
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Purdue University
Neurofibromatosis Type 1, Reading Disabilities
Neurobiology and Treatment of Reading Disability in NF-1
The goal of this trial is to determine if children with neurofibromatosis type 1 who have reading disabilities respond the same way-both behaviorally and neurobiologically-to specialized treatment programs as children with…
- Trial name
- NCT00624234
- Testing
- Tutoring Program I, Tutoring Program II
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Mental Disorders
A Randomized Controlled Trial of Mental Health Peer-Led Education
This randomized controlled trial tests the efficacy of a mental health peer-led educational intervention called BRIDGES (Building Recovery of Individual Dreams and Goals through Education and Support).
- Trial name
- BRIDGES (NCT01297985)
- Testing
- BRIDGES Peer-Led Education
- Where
- United States
- Volunteers
- 428 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.
- Trial name
- NCT00754013
- Testing
- Aricept (Donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Visual Rehabilitation, Visual Impairment, Autism Spectrum Disorder, Developmental Disabilities, Intellectual Disability, Behavioral Symptoms
Evaluation of a Program to Enhance Ophthalmic Compliance in Children and Adolescents With Special Needs
The goal of this clinical trial is to learn about the effects of the structured program incorporating contextual, behavioral, and cognitive strategies to improve compliance of children and adolescents with special needs during…
- Trial name
- NCT06717282
- Testing
- visual rehabilitation for ophthalmic compliance, Using contextual, behavioral, and cognitive-based stragegies to develop training programs
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Fragile X Syndrome
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
This trial will evaluate the efficacy and safety of ZYN002, a clear cannabidiol gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X Syndrome…
- Trial name
- CONNECT-FX (NCT03614663)
- Testing
- ZYN002 - Cannabidiol Transdermal Gel
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Zynerba Pharmaceuticals, Inc.
Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
The purpose of the study is to collect preliminary data on whether the drug adalimumab (also called Humira) can decrease pain and stiffness, improve quality of life, and is safe in people with mucopolysaccharidosis type I, II, or…
- Conditions
- Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
- Trial name
- NCT02437253
- Testing
- Adalimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Depression
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
This study will evaluate the safety and effectiveness of methylphenidate in improving cognition and function in older adults with depression.
- Trial name
- NCT00602290
- Testing
- Citalopram, Methylphenidate (MPH)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of California, Los Angeles
Down Syndrome
Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)
This study will examine the feasibility of the Promoting Health through Parent Empowerment and the Activation of Routines (Pro-PEAR) intervention using a open case-series for intervention optimization followed by a pilot RCT in…
- Trial name
- Pro-PEAR (NCT05020366)
- Testing
- Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Growth & Development, Child Development
Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit
The purpose of this study is to evaluate the efficacy of individualized performance feedback coupled with an educational module in improving resident performance of the physical and developmental examination component of…
- Conditions
- Growth & Development, Child Development, Internship and Residency, Education, Medical
- Trial name
- NCT00465361
- Testing
- performance feedback with an educational module
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's Mercy Hospital Kansas City
Down Syndrome
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
The purpose of this 16-week research study is to determine whether a drug called memantine hydrochloride (memantine) has the potential to help improve memory and other cognitive abilities of young adults with Down syndrome (DS).
- Trial name
- NCT01112683
- Testing
- Memantine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Colorado, Denver
Communicable Diseases, Prevention
SAFE Workplace Intervention for People With IDD
The purpose of this study is to examine the feasibility and efficacy of a systematic training approach targeting behaviors to increase safety and prevention of airborne diseases such as COVID-19 in the workplace for individuals…
- Conditions
- Communicable Diseases, Prevention, Workplace Intervention
- Trial name
- NCT06112249
- Testing
- SAFE Employment Training
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Temple University
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Down Syndrome
Down Syndrome Speech Intelligibility Diagnostic Treatment Study
The 'Down syndrome speech intelligibility diagnostic treatment study' is a pilot clinical intervention study assessing the efficacy of an integrative speech treatment approach for individuals with Down syndrome (DS).
- Trial name
- NCT04059354
- Testing
- Speech therapy addressing phonology and motor learning
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Hunter Syndrome
Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
This study is being conducted to identify pediatric patients with Hunter syndrome who have neurodevelopmental disease characteristics, who are currently receiving treatment with Elaprase, and who may be suitable to participate in…
- Trial name
- NCT00937794
- Testing
- Neurobehavioral testing, Visual and auditory assessments
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Shire
Rett Syndrome
A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
This 2 cohort, sequential, ascending dose study will assess the safety, tolerability and efficacy of oral ketamine dosed in a single 5-day BID regimen in addition to placebo, in a 4-week cross-over design in patients with Rett…
- Trial name
- NCT03633058
- Testing
- Ketamine
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Rett Syndrome Research Trust
Prader-Willi Syndrome
A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome
This was a study investigating RAD011 in participants diagnosed with Prader-Willi Syndrome (PWS). The primary objective of the Phase 2 part of this study was to assess the safety and tolerability of multiple dose levels of RAD011…
- Trial name
- NCT05098509
- Testing
- RAD011
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Prader-Willi Syndrome
A Study of GLWL-01 in Patients With Prader-Willi Syndrome
The aim of this study is to evaluate efficacy, safety, and pharmacokinetics of GLWL-01 in the treatment of patients with Prader-Willi Syndrome (PWS).
- Trial name
- NCT03274856
- Testing
- GLWL-01
- Where
- 7 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- GLWL Research Inc.
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone.
- Trial name
- REMAIN (NCT01142466)
- Testing
- Interferon beta-1a (Rebif)
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany